NCT05901545View on ClinicalTrials.gov

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

August 22, 2023

Primary Completion Date

November 30, 2028

Study Completion Date

November 30, 2029

Conditions
Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell Carcinoma
Interventions
BIOLOGICAL

Panitumumab

Given by IV

OTHER

Indium In 111 Panitumumab

Given by IV

PROCEDURE

Single Photon Emission Computed Tomography

Undergo SPECT/CT

PROCEDURE

Computed Tomography

Undergo SPECT/CT

PROCEDURE

Surgical Procedure

Undergo standard of care surgery

OTHER

Imaging agent

Receive local injection of optical dye

PROCEDURE

Intraoperative Imaging

Undergo Intraoperative Imaging

PROCEDURE

Near Infrared Imaging

Undergo Near Infrared Imaging

PROCEDURE

Electrocardiography

Undergo Electrocardiography

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

Trial Locations (1)

37232

RECRUITING

Vanderbilt University/Ingram Cancer Center, Nashville

All Listed Sponsors
collaborator

American Cancer Society, Inc.

OTHER

lead

Vanderbilt-Ingram Cancer Center

OTHER